Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucagon Elimination in CKD and Liver Cirrhosis
NCT05056584Completed
- Sponsor
- Gentofte Hospital
- Start
- Aug 2020
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of glucagon in chronic kidney disease (CKD) and Liver cirrhosis (LC) (3 arms), sponsored by Gentofte Hospital. Primary endpoint: Metabolic clearance rate of glucagon at 50 minutes. Started Aug 2020; status: completed.
02
Drugs
glucagon
03
Conditions
chronic kidney disease (CKD)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT05056584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056584.